Althera names Dr. Arun Maseeh vice president of medical affairs

By AI, Created 3:26 PM UTC, June 04, 2026, /AGP/ – Althera Laboratories has appointed physician-scientist Dr. Arun Maseeh as vice president of medical affairs as the company expands its cardiovascular and metabolic portfolio across multiple international markets. The move brings a senior leader with more than 25 years of experience into a role focused on evidence generation, scientific engagement and new product development.

Why it matters: - Althera Laboratories is adding a senior medical leader as it tries to scale its cardiovascular and metabolic business across Europe, Asia, Latin America, Africa and other international markets. - The appointment is meant to strengthen evidence generation, scientific engagement and new product development at a time when the company is building its portfolio. - Dr. Patrick Aubonnet’s move to senior advisor keeps clinical-trial oversight and strategy continuity in place during the transition.

What happened: - Althera Laboratories appointed Dr. Arun Maseeh, MD, as vice president of medical affairs. - The company said the appointment was announced June 4, 2026. - Dr. Patrick Aubonnet, MD, is transitioning to senior advisor to the board on key clinical trials and related matters. - Dr. Maseeh will report to Chairman and CEO Sanjeev Agarwal and work with the executive team and Dr. Aubonnet.

The details: - Dr. Maseeh brings more than 25 years of pharmaceutical industry leadership experience. - His background spans medical affairs, clinical development, clinical research, scientific communications, regulatory strategy and product innovation. - His career has included leadership roles at Cadila Pharma, Syneos, Novartis, Biocon, Troikaa and Torrent Pharmaceuticals. - He has led global and regional programs in cardiometabolic medicine, oncology, gastroenterology, infectious diseases, respiratory medicine, immunology and neuroscience. - Dr. Maseeh earned an MBBS from Christian Medical College, Vellore, and an MD in internal medicine from Christian Medical College, Ludhiana. - His work included leadership in the Polycap program, including The Indian Polycap Study (TIPS), published in The Lancet, and the Wellcome Trust-funded TIPS-3 cardiovascular outcomes study, published in The New England Journal of Medicine. - Those studies helped build the evidence base for fixed-dose cardiovascular prevention strategies and wider acceptance of cardiovascular polypill therapy. - His scientific contributions also include work on intravenous rabeprazole, the multinational IMPI Trial in tuberculous pericarditis and global clinical development programs across several therapeutic areas. - Dr. Maseeh also serves as a scientific reviewer and advisor for multiple peer-reviewed journals. - The Annals of Internal Medicine recognized him as an Outstanding Manuscript Reviewer.

Between the lines: - Althera is signaling that medical affairs is central to its next phase, not just a support function. - The company is pairing a new medical affairs leader with a board-level clinical advisor, which suggests it wants both faster execution and continuity on high-stakes development decisions. - Dr. Maseeh’s background in cardiovascular prevention studies lines up closely with Althera’s stated focus on cardiovascular and metabolic therapies.

What’s next: - Dr. Maseeh will help advance Althera’s evidence-generation strategy, scientific engagement initiatives and new product development programs. - He will also work with colleagues across Althera and Vibonum, along with healthcare partners, investigators and scientific collaborators worldwide. - Althera will continue expanding its therapies and manufacturing capabilities through its integrated scientific, manufacturing and regulatory platform.

The bottom line: - Althera is betting that a veteran physician-scientist can help accelerate its global growth and deepen the clinical credibility of its cardiovascular and metabolic pipeline.